NeuroAiD was first known a Traditional Chinese Medicine drug marketed in China for approved-indication of cerebral infarction’s functional and neurological deficits, i.e. helping patient recover from their disabilities after a stroke.
We identified in China a promising natural drug known as NeuroAiD internationally for which data from research conducted in China shows a high efficacy in improving stroke rehabilitation, even at a late stage (subjects started treatment 2 weeks to 6 months after their stroke).
The CHIMES-E protocol was published in March 2013 in Cerebrovascular Diseases
The CHIMES-I protocol was published in August 2013 in International Journal of Stroke
